Potential role of interleukin-18 in liver disease associated with insulin resistance

Obesity Research

Volumn 13, Issue 11, 2005, Pages 1925-1931

  López Bermejo, Abel ^a   Bosch, Montserrat ^a   Recasens, Monica ^a   Biarnés, Josefina ^a   Esteve, Eduardo ^a   Casamitjana, Roser ^b   Vendrell, Joan ^c   Ricart, Wifredo ^a   Fernández Real, José Manuel ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; BMI; Fatty liver disease; glutamyltransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; INSULIN; INTERLEUKIN 18; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; LIVER; LIVER DISEASE; LIVER FUNCTION TEST; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; CHOLESTEROL; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-18; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 33644831807     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2005.237     Document Type: Article

References (40)

1. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6:87-97.
2. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842-5.
3. Ohlson LO, Larsson B, Björntorp P, et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia. 1988;31:798-805.
4. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care. 1998;21:732-7.
5. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889-95.
6. Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004;53:2623-32.
7. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000;49:749-58.
8. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87:3023-8.
9. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-5.
10. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002; 17(suppl):S186-90.
11. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoll M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893-4.
12. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:1008-17.
13. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis. Hepatology. 2004;39:188-96.
14. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003;73:213-24.
15. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL. Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002;195:245-57.
16. Lee MO, Choi YH, Shin EC, et al. Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection. J Hepatol. 2002;37:380-6.
17. Esposito K, Pontillo A, Ciotola M, et al. Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab. 2002;87:3864-6.
18. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106: 2067-72.
19. Esposito K, Nappo F, Giugliano F, et al. Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care. 2003;26:1647.
20. Esposito K, Nappo F, Giugliano F, et al. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2003;78:1135-40.
21. Aso Y, Okumura K, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care. 2003;26:2622-7.
22. Moriwaki Y, Yamamoto T, Shibutani Y, et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism. 2003;52:605-8.
23. Mallat Z, Henry P, Fressonnet R, et al. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart. 2002;88:467-9.
24. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106:24-30.
25. Blankenberg S, Luc G, Ducimetiere P, et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003;108:2453-9.
26. Lopez-Bermejo A, Botas P, Funahashi T, et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf). 2004;60:256-63.
27. Fernandez-Real JM, Lopez-Bermejo A, Broch M, Yendrell J, Richart C, Ricart W. Circulating soluble CD14 monocyte receptor is associated with increased alanine aminotransferase. Clin Chem. 2004;50:1456-8.
28. Fernandez-Real JM, Broch M, Ricart W, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes. 1998;47:1757-62.
29. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995;378:88-91.
30. Faggioni R, Jones-Carson J, Reed DA, et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci USA. 2000;97:2367-72.
31. Takeuchi D, Yoshidome H, Kato A, et al. Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology. 2004;39:699-710.
32. Sakao Y, Takeda K, Tsutsui H, et al. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int Immunol. 1999;11:471-80.
33. Finotto S, Siebler J, Hausding M, et al. Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo. Gut. 2004;53:392-400.
34. Ludwiczek O, Kaser A, Novick D, et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol. 2002;22:331-7.
35. Hirota M, Shibata M, Ogawa M. Increased concentrations of plasma interleukin-18 in patients with hepatic failure 1 week after surgery. J Immunother. 2002;25(Suppl 1):S75-7.
36. Yumoto E, Higashi T, Nouso K, et al. Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J Castroenterol Hepatol. 2002;17:285-94.
37. Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krzych U, Diehl AM. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology. 2000;31:633-40.
38. Roderick P. Liver function tests: defining what's normal. BMJ. 2004;328:987.
39. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Thl and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12:53-72.
40. Dao T, Mehal WZ, Crispe IN. IL-18 augments perforindependent cytotoxicity of liver NK-T cells. J Immunol. 1998;161:2217-22.